Association of COVID-19 with Comorbidities: An Update
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F23%3A00133384" target="_blank" >RIV/00216224:14110/23:00133384 - isvavai.cz</a>
Result on the web
<a href="https://pubs.acs.org/doi/10.1021/acsptsci.2c00181" target="_blank" >https://pubs.acs.org/doi/10.1021/acsptsci.2c00181</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1021/acsptsci.2c00181" target="_blank" >10.1021/acsptsci.2c00181</a>
Alternative languages
Result language
angličtina
Original language name
Association of COVID-19 with Comorbidities: An Update
Original language description
Coronavirus disease (COVID-19) is caused by severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) which was identified in Wuhan, China in December 2019 and jeopardized human lives. It spreads at an unprecedented rate worldwide, with serious and still-unfolding health conditions and economic ramifications. Based on the clinical investigations, the severity of COVID-19 appears to be highly variable, ranging from mild to severe infections including the death of an infected individual. To add to this, patients with comorbid conditions such as age or concomitant illnesses are significant predictors of the disease's severity and progression. SARS-CoV-2 enters inside the host cells through ACE2 (angiotensin converting enzyme2) receptor expression; therefore, comorbidities associated with higher ACE2 expression may enhance the virus entry and the severity of COVID-19 infection. It has already been recognized that age-related comorbidities such as Parkinson's disease, cancer, diabetes, and cardiovascular diseases may lead to life-threatening illnesses in COVID-19-infected patients. COVID-19 infection results in the excessive release of cytokines, called "cytokine storm", which causes the worsening of comorbid disease conditions. Different mechanisms of COVID-19 infections leading to intensive care unit (ICU) admissions or deaths have been hypothesized. This review provides insights into the relationship between various comorbidities and COVID-19 infection. We further discuss the potential pathophysiological correlation between COVID-19 disease and comorbidities with the medical interventions for comorbid patients. Toward the end, different therapeutic options have been discussed for COVID-19-infected comorbid patients.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30105 - Physiology (including cytology)
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2023
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE
ISSN
2575-9108
e-ISSN
2575-9108
Volume of the periodical
6
Issue of the periodical within the volume
3
Country of publishing house
US - UNITED STATES
Number of pages
21
Pages from-to
334-354
UT code for WoS article
000939529100001
EID of the result in the Scopus database
2-s2.0-85149135686